Novartis Looks Appealing, Based on Drug Pipeline and Planned Spinoff

Novartis develops branded, innovative drugs. Novartis has an extensive number of cancer treatments and is a leader in cell and gene therapy. Its generic-drug business, Sandoz, produces complex injectable drugs (i.e., biosimilars). Read More...


Billionaire Ken Griffin Goes in on These 3 ‘Strong Buy’ Stocks

As fears of high inflation and the threat of recession become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $50 billion worth of assets under management. As a 19-year-old sophomore at Harvard University, Griffin began trading from his dorm room with a fax machine, computer and phone. Now, the CEO of Citadel, whose net worth stands at $27 billion, is known as one of the Wall Street

Read More

Add Comment

Click here to post a comment